Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life – A Case Study of the Innovative Medicines Initiative. Issue 4 (30th May 2020)

• Record Type: Journal Article
• Authors: Happich, Michael; Brnabic, Alan; Faries, Douglas; Abrams, Keith; Winfree, Katherine B.; Girvan, Allicia; Jonsson, Pall; Johnston, Joseph; Belger, Mark
• Is Part Of: Clinical pharmacology & therapeutics. Volume 108:Issue 4(2020)
• Page Start: 817
• Page End: 825
• Publication Date: 2020-05-30
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.1854
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Evidence from randomized controlled trials available for timely health technology assessments of new pharmacological treatments and regulatory decision making may not be generalizable to local patient populations, often resulting in decisions being made under uncertainty. In recent years, several reweighting approaches have been explored to address this important question of generalizability to a target population. We present a case study of the Innovative Medicines Initiative to illustrate the inverse propensity score reweighting methodology, which may allow us to estimate the expected treatment benefit if a clinical trial had been run in a broader real‐world target population. We learned that identifying treatment effect modifiers, understanding and managing differences between patient characteristic data sets, and balancing the closeness of trial and target patient populations with effective sample size are key to successfully using this methodology and potentially mitigating some of this uncertainty around local decision making.